Scientific Presentation at British Neuro-Oncology Annual Meeting Shows Original Analysis of Survival Extension Was Likely UnderestimatedBETHESDA, Md., July 8, 2026 /PRNewswire/ — Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor…

Read the full release →

News provided by PR Newswire.